Annovis Bio

View All

Pharma News for Kyverna, Annovis, Astellas, FibroGen
FDA Fast Track Status to Kyverna’s KYV-101; Annovis’s Phase III Study for Buntanetap; Gilteritinib Demonstrated Benefit in AML Patients; FDA Orphan Drug Designation to DTx Pharma’s DTx-1252; FibroGen’s LELANTOS-1 Phase 3 Clinical Study Result

FDA Grants Fast Track Status to KYV-101 for Refractory Lupus Nephritis Treatment Kyverna Therapeutics announced that the FDA has given Fast Track status to KYV-101, a treatment for patients suffering from resistant lupus nephritis (LN). KYV-101 is an innovative therapy that uses anti-CD19 chimeric antigen recept...

Find More

pharma news
Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey

A Philadelphia-based pharmaceutical, Annovis Bio, has raised USD12 million by listing its 2 million shares at USD 6 each. The company has managed to net USD 2 million more by offering 40% more shares.  The company plans to use the funds raised to address the unmet needs in the Alzheimer’s disease market...

Find More